Identification

Name
Sodium phosphate
Accession Number
DB09449  (DB09127, DB11083, DB09524, DB09542, DB09468, DB11084, DB09482, DB09469, DB09525)
Type
Small Molecule
Groups
Approved
Description

Sodium phosphate is a saline laxative that is thought to work by increasing fluid in the small intestine. It usually results in a bowel movement after 30 minutes to 6 hours.

Structure
Thumb
Synonyms
  • Sodium orthophosphate
  • Sodium phosphate monobasic
  • Sodium phosphate monobasic (anhydrate)
  • Sodium phosphate, unspecified
  • Sodium phosphates
Product Ingredients
IngredientUNIICASInChI Key
Sodium phosphate, dibasicBWZ7K44R5110140-65-5LVXHNCUCBXIIPE-UHFFFAOYSA-L
Sodium phosphate, dibasic dihydrate94255I6E2T10028-24-7KDQPSPMLNJTZAL-UHFFFAOYSA-L
Sodium phosphate, dibasic dodecahydrateE1W4N241FO10039-32-4DGLRDKLJZLEJCY-UHFFFAOYSA-L
Sodium phosphate, dibasic, anhydrous22ADO53M6F7558-79-4BNIILDVGGAEEIG-UHFFFAOYSA-L
Sodium phosphate, dibasic, heptahydrate70WT22SF4B7782-85-6PYLIXCKOHOHGKQ-UHFFFAOYSA-L
Sodium phosphate, monobasic, anhydrousNot Available7558-80-7AJPJDKMHJJGVTQ-UHFFFAOYSA-M
Sodium phosphate, monobasic, dihydrate5QWK66595613472-35-0VBJGJHBYWREJQD-UHFFFAOYSA-M
Sodium phosphate, monobasic, monohydrate593YOG76RN10049-21-5BBMHARZCALWXSL-UHFFFAOYSA-M
Sodium phosphate, monobasic, unspecified form3980JIH2SWNot AvailableNot applicable
Product Images
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
IMUFLEX WB-RP Blood Bag System with Integral Whole Blood Leukocyte Reduction Filter (Removing Platelets) with Diversion Blood Sampling Arm Anticoagulant Citrate Phosphate Dextrose (CPD) AND OPTISOL (AS-5) Red Cell PreservativeKitIntravenousTerumo Corporation2010-02-26Not applicableUs
IMUFLEX WB-SP Blood Bag System with Integral Whole Blood Leukocyte Reduction Filter (Saving Platelets) with Diversion Blood Sampling Arm Anticoagulant Citrate Phosphate Dextrose (CPD) AND OPTISOL (AS-5) Red Cell PreservativeKitIntravenousTerumo Corporation2010-12-15Not applicableUs
Leucoflex CGPKitMaco Productions2013-05-31Not applicableUs
MTL1 LeucoflexKitIntravenousMaco Productions2005-11-21Not applicableUs
TERUFLEX Blood Bag System Anticoagulant Citrate Phosphate Dextrose (CPD) AND OPTISOL Red Cell PreservativeKitIntravenousTerumo Corporation2009-12-15Not applicableUs
TERUFLEX Blood Bag System with Blood Sampling Arm Anticoagulant Citrate Phosphate Dextrose (CPD) AND OPTISOL (AS-5) Red Cell PreservativeKitIntravenousTerumo Corporation2010-05-05Not applicableUs
TERUFLEX Blood Bag System with Diversion Blood Sampling Arm Anticoagulant Citrate Phosphate Dextrose (CPD) AND OPTISOL (AS-5) Red Cell PreservativeKitIntravenousTerumo Corporation2010-05-05Not applicableUs
Mixture Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing End
Additive Solution Formula 3 As-3Sodium phosphate, monobasic, monohydrate (0.276 g) + Adenine (0.030 g) + Citric acid monohydrate (0.042 g) + Glucose (1.10 g) + Sodium Chloride (0.410 g) + Sodium citrate dihydrate (0.588 g)SolutionUnknownTerumo Bct, Inc.2013-05-31Not applicableCanada
ADSOL Red Cell Preservation Solution System in Plastic Container (PL 146 Plastic)Sodium phosphate, monobasic, monohydrate (155 mg/70mL) + Adenine (30 mg/110mL) + Citric Acid (209 mg/70mL) + Dextrose monohydrate (1.78 g/70mL) + Dextrose monohydrate (2.42 g/110mL) + Mannitol (825 mg/110mL) + Sodium Chloride (990 mg/110mL) + Sodium citrate dihydrate (1.84 g/70mL)KitFenwal, Inc.2007-03-01Not applicableUs
ADSOL Red Cell Preservation Solution System in Plastic Container (PL 146 Plastic)Sodium phosphate, monobasic, monohydrate (155 mg/70mL) + Adenine (30 mg/110mL) + Citric Acid (209 mg/70mL) + Dextrose monohydrate (1.78 g/70mL) + Dextrose monohydrate (2.42 g/110mL) + Mannitol (825 mg/110mL) + Sodium Chloride (990 mg/110mL) + Sodium citrate dihydrate (1.84 g/70mL)KitFenwal, Inc.2009-05-15Not applicableUs
ADSOL Red Cell Preservation Solution System in Plastic Container (PL 146 Plastic)Sodium phosphate, monobasic, monohydrate (155 mg/70mL) + Adenine (30 mg/110mL) + Citric Acid (209 mg/70mL) + Dextrose monohydrate (1.78 g/70mL) + Dextrose monohydrate (2.42 g/110mL) + Mannitol (825 mg/110mL) + Sodium Chloride (990 mg/110mL) + Sodium citrate dihydrate (1.84 g/70mL)KitFenwal, Inc.2007-03-01Not applicableUs
ADSOL Red Cell Preservation Solution System in Plastic Container (PL 146 Plastic)Sodium phosphate, monobasic, monohydrate (155 mg/70mL) + Adenine (30 mg/110mL) + Citric Acid (209 mg/70mL) + Dextrose monohydrate (1.78 g/70mL) + Dextrose monohydrate (2.42 g/110mL) + Mannitol (825 mg/110mL) + Sodium Chloride (990 mg/110mL) + Sodium citrate dihydrate (1.84 g/70mL)KitFenwal, Inc.2007-06-06Not applicableUs
ADSOL Red Cell Preservation Solution System in Plastic Container (PL 146 Plastic)Sodium phosphate, monobasic, monohydrate (155 mg/70mL) + Adenine (30 mg/110mL) + Citric Acid (209 mg/70mL) + Dextrose monohydrate (1.78 g/70mL) + Dextrose monohydrate (2.42 g/110mL) + Mannitol (825 mg/110mL) + Sodium Chloride (990 mg/110mL) + Sodium citrate dihydrate (1.84 g/70mL)KitFenwal, Inc.2007-06-11Not applicableUs
ADSOL Red Cell Preservation Solution System in Plastic Container (PL 146 Plastic)Sodium phosphate, monobasic, monohydrate (140 mg/63mL) + Adenine (27 mg/100mL) + Citric Acid (188 mg/63mL) + Dextrose monohydrate (1.61 g/63mL) + Dextrose monohydrate (2.2 g/100mL) + Mannitol (750 mg/100mL) + Sodium Chloride (900 mg/100mL) + Sodium citrate dihydrate (1.66 g/63mL)KitFenwal, Inc.2010-09-28Not applicableUs
ADSOL Red Cell Preservation Solution System in Plastic Container (PL 146 Plastic)Sodium phosphate, monobasic, monohydrate (155 mg/70mL) + Adenine (30 mg/110mL) + Citric Acid (209 mg/70mL) + Dextrose monohydrate (1.78 g/70mL) + Dextrose monohydrate (2.42 g/110mL) + Mannitol (825 mg/110mL) + Sodium Chloride (990 mg/110mL) + Sodium citrate dihydrate (1.84 g/70mL)KitFenwal, Inc.2007-03-01Not applicableUs
ADSOL Red Cell Preservation Solution System in Plastic Container (PL 146 Plastic)Sodium phosphate, monobasic, monohydrate (140 mg/63mL) + Adenine (27 mg/100mL) + Citric Acid (188 mg/63mL) + Dextrose monohydrate (1.61 g/63mL) + Dextrose monohydrate (2.2 g/100mL) + Mannitol (750 mg/100mL) + Sodium Chloride (900 mg/100mL) + Sodium citrate dihydrate (1.66 g/63mL)KitFenwal, Inc.2007-03-01Not applicableUs
ADSOL Red Cell Preservation Solution System in Plastic Container (PL 146 Plastic)Sodium phosphate, monobasic, monohydrate (155 mg/70mL) + Adenine (30 mg/110mL) + Citric Acid (209 mg/70mL) + Dextrose monohydrate (1.78 g/70mL) + Dextrose monohydrate (2.42 g/110mL) + Mannitol (825 mg/110mL) + Sodium Chloride (990 mg/110mL) + Sodium citrate dihydrate (1.84 g/70mL)KitFenwal, Inc.2007-03-01Not applicableUs
Unapproved/Other Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing End
Azuphen MbSodium phosphate, monobasic, monohydrate (40.8 mg/1) + Hyoscyamine sulfate (.12 mg/1) + Methenamine (120 mg/1) + Methylene blue (10 mg/1) + Phenyl salicylate (36 mg/1)CapsuleOralBurel Pharmaceuticals, Llc2015-09-282018-01-06Us
Dibasic Sodium Phosphate, Monobasic Potassium Phosphate and Monobasic Sodium PhosphateSodium phosphate, dibasic, anhydrous (852 mg/1) + Sodium phosphate, monobasic, monohydrate (130 mg/1) + Monopotassium phosphate (155 mg/1)TabletOralCardinal Health2012-06-282018-05-23Us
Dibasic Sodium Phosphate, Monobasic Potassium Phosphate and Monobasic Sodium PhosphateSodium phosphate, dibasic, anhydrous (852 mg/1) + Sodium phosphate, monobasic, monohydrate (130 mg/1) + Monopotassium phosphate (155 mg/1)TabletOralAvera Mc Kennan Hospital2015-03-112018-06-07Us
Dibasic Sodium Phosphate, Monobasic Potassium Phosphate and Monobasic Sodium PhosphateSodium phosphate, dibasic, anhydrous (852 mg/1) + Sodium phosphate, monobasic, monohydrate (130 mg/1) + Monopotassium phosphate (155 mg/1)TabletOralAmerincan Health Packaging2014-06-02Not applicableUs
Dibasic Sodium Phosphate, Monobasic Potassium Phosphate and Monobasic Sodium PhosphateSodium phosphate, dibasic, anhydrous (852 mg/1) + Sodium phosphate, monobasic, monohydrate (130 mg/1) + Monopotassium phosphate (155 mg/1)TabletOralRising Pharmaceuticals2012-06-28Not applicableUs
Dibasic Sodium Phosphate, Monobasic Potassium Phosphate and Monobasic Sodium PhosphateSodium phosphate, dibasic, anhydrous (852 mg/1) + Sodium phosphate, monobasic, monohydrate (130 mg/1) + Monopotassium phosphate (155 mg/1)TabletOralCarilion Materials Management2012-06-28Not applicableUs64980 0104 01 nlmimage10 cc046643
Dibasic Sodium Phosphate, Monobasic Potassium Phosphate and Monobasic Sodium PhosphateSodium phosphate, dibasic, anhydrous (852 mg/1) + Sodium phosphate, monobasic, monohydrate (130 mg/1) + Monopotassium phosphate (155 mg/1)TabletOralKaiser Foundations Hospitals2014-07-07Not applicableUs
Dibasic Sodium Phosphate, Monobasic Potassium Phosphate and Monobasic Sodium PhosphateSodium phosphate, dibasic, anhydrous (852 mg/1) + Sodium phosphate, monobasic, monohydrate (130 mg/1) + Monopotassium phosphate (155 mg/1)TabletOralAmerincan Health Packaging2014-06-02Not applicableUs
Dibasic Sodium Phosphate, Monobasic Potassium Phosphate and Monobasic Sodium PhosphateSodium phosphate, dibasic, anhydrous (852 mg/1) + Sodium phosphate, monobasic, monohydrate (130 mg/1) + Monopotassium phosphate (155 mg/1)TabletOralCardinal Health2012-06-282018-05-23Us
Dibasic Sodium Phosphate, Monobasic Potassium Phosphate and Monobasic Sodium PhosphateSodium phosphate, dibasic, anhydrous (852 mg/1) + Sodium phosphate, monobasic, monohydrate (130 mg/1) + Monopotassium phosphate (155 mg/1)TabletOralAvera Mc Kennan Hospital2015-03-112018-06-07Us
Categories
UNII
KH7I04HPUU
CAS number
7632-05-5
Weight
Average: 119.977
Monoisotopic: 119.958839739
Chemical Formula
H2NaO4P
InChI Key
AJPJDKMHJJGVTQ-UHFFFAOYSA-M
InChI
InChI=1S/Na.H3O4P/c;1-5(2,3)4/h;(H3,1,2,3,4)/q+1;/p-1
IUPAC Name
sodium dihydrogen phosphate
SMILES
[Na+].OP(O)([O-])=O

Pharmacology

Indication

Used to treat constipation or to clean the bowel before a colonoscopy [FDA Label].

Associated Conditions
Associated Therapies
Pharmacodynamics

Sodium phosphate inceases fecal water content to increase mobility through the large intestine [1].

Mechanism of action

Sodium phosphate is thought to work by increasing the amount of solute present in the intestinal lumen thereby creating an osmotic gradient which draws water into the lumen [1].

Absorption

Tmax for phosphate absorption with orally administered liquid sodium phosphate is 1-3h [3].

Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity

Intamuscular LD50 of 250mg/kg and oral LD50 of 8290 mg/kg reported in rats [7]. Phosphate toxicity is likely due to the disturbance of other electrolytes when phosphate levels are high, producing symptoms including tetany, dehydration, hypotension, tachycardia, hyperpyrexia, cardiac arrest and coma [4]. Risk of raising phosphate levels through use of sodium phosphate appears to be higher in smaller patients [3].

Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
(4R)-limoneneSodium phosphate may increase the nephrotoxic activities of (4R)-limonene.Investigational
AceclofenacSodium phosphate may increase the nephrotoxic activities of Aceclofenac.Approved, Investigational
AcemetacinSodium phosphate may increase the nephrotoxic activities of Acemetacin.Approved, Experimental, Investigational
AcetazolamideAcetazolamide may increase the nephrotoxic activities of Sodium phosphate.Approved, Vet Approved
Acetylsalicylic acidSodium phosphate may increase the nephrotoxic activities of Acetylsalicylic acid.Approved, Vet Approved
AdapaleneSodium phosphate may increase the nephrotoxic activities of Adapalene.Approved
AlclofenacSodium phosphate may increase the nephrotoxic activities of Alclofenac.Approved, Withdrawn
AlmasilateAlmasilate can cause a decrease in the absorption of Sodium phosphate resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Experimental
AlminoprofenSodium phosphate may increase the nephrotoxic activities of Alminoprofen.Experimental
AloglutamolAloglutamol can cause a decrease in the absorption of Sodium phosphate resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
AluminiumAluminium can cause a decrease in the absorption of Sodium phosphate resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
Aluminium acetoacetateAluminium acetoacetate can cause a decrease in the absorption of Sodium phosphate resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
Aluminium glycinateAluminium glycinate can cause a decrease in the absorption of Sodium phosphate resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
Aluminum hydroxideAluminum hydroxide can cause a decrease in the absorption of Sodium phosphate resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
AmilorideAmiloride may increase the nephrotoxic activities of Sodium phosphate.Approved
AmineptineThe risk or severity of adverse effects can be increased when Amineptine is combined with Sodium phosphate.Illicit, Withdrawn
AmitriptylineThe risk or severity of adverse effects can be increased when Amitriptyline is combined with Sodium phosphate.Approved
AmitriptylinoxideThe risk or severity of adverse effects can be increased when Amitriptylinoxide is combined with Sodium phosphate.Approved, Investigational
AmoxapineThe risk or severity of adverse effects can be increased when Amoxapine is combined with Sodium phosphate.Approved
AndrographolideSodium phosphate may increase the nephrotoxic activities of Andrographolide.Investigational
AnisodamineSodium phosphate may increase the nephrotoxic activities of Anisodamine.Investigational
AntipyrineSodium phosphate may increase the nephrotoxic activities of Antipyrine.Approved, Investigational
ApocyninSodium phosphate may increase the nephrotoxic activities of Apocynin.Investigational
ApremilastSodium phosphate may increase the nephrotoxic activities of Apremilast.Approved, Investigational
AzapropazoneSodium phosphate may increase the nephrotoxic activities of Azapropazone.Withdrawn
AzelastineSodium phosphate may increase the nephrotoxic activities of Azelastine.Approved
Azilsartan medoxomilAzilsartan medoxomil may increase the nephrotoxic activities of Sodium phosphate.Approved, Investigational
AzosemideAzosemide may increase the nephrotoxic activities of Sodium phosphate.Investigational
BalsalazideSodium phosphate may increase the nephrotoxic activities of Balsalazide.Approved, Investigational
BenazeprilBenazepril may increase the nephrotoxic activities of Sodium phosphate.Approved, Investigational
BendazacSodium phosphate may increase the nephrotoxic activities of Bendazac.Experimental
BendroflumethiazideBendroflumethiazide may increase the nephrotoxic activities of Sodium phosphate.Approved
BenorilateSodium phosphate may increase the nephrotoxic activities of Benorilate.Experimental
BenoxaprofenSodium phosphate may increase the nephrotoxic activities of Benoxaprofen.Withdrawn
BenzydamineSodium phosphate may increase the nephrotoxic activities of Benzydamine.Approved
BevoniumSodium phosphate may increase the nephrotoxic activities of Bevonium.Experimental
Bismuth SubcitrateBismuth Subcitrate can cause a decrease in the absorption of Sodium phosphate resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
Bismuth subnitrateBismuth subnitrate can cause a decrease in the absorption of Sodium phosphate resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
BromfenacSodium phosphate may increase the nephrotoxic activities of Bromfenac.Approved
BromotheophyllineBromotheophylline may increase the nephrotoxic activities of Sodium phosphate.Approved
BucillamineSodium phosphate may increase the nephrotoxic activities of Bucillamine.Investigational
BufexamacSodium phosphate may increase the nephrotoxic activities of Bufexamac.Approved, Experimental
BumadizoneSodium phosphate may increase the nephrotoxic activities of Bumadizone.Experimental
BumetanideBumetanide may increase the nephrotoxic activities of Sodium phosphate.Approved
ButriptylineThe risk or severity of adverse effects can be increased when Butriptyline is combined with Sodium phosphate.Approved
Calcium AcetateCalcium Acetate can cause a decrease in the absorption of Sodium phosphate resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
Calcium CarbonateCalcium Carbonate can cause a decrease in the absorption of Sodium phosphate resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
Calcium ChlorideCalcium Chloride can cause a decrease in the absorption of Sodium phosphate resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Calcium CitrateCalcium Citrate can cause a decrease in the absorption of Sodium phosphate resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Calcium glubionateCalcium glubionate can cause a decrease in the absorption of Sodium phosphate resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Calcium GluceptateCalcium Gluceptate can cause a decrease in the absorption of Sodium phosphate resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Calcium gluconateCalcium gluconate can cause a decrease in the absorption of Sodium phosphate resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Vet Approved
Calcium lactateCalcium lactate can cause a decrease in the absorption of Sodium phosphate resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational, Vet Approved
Calcium lactate gluconateCalcium lactate gluconate can cause a decrease in the absorption of Sodium phosphate resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
Calcium levulinateCalcium levulinate can cause a decrease in the absorption of Sodium phosphate resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Experimental
Calcium pangamateCalcium pangamate can cause a decrease in the absorption of Sodium phosphate resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
Calcium PhosphateCalcium Phosphate can cause a decrease in the absorption of Sodium phosphate resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Calcium silicateCalcium silicate can cause a decrease in the absorption of Sodium phosphate resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
CandesartanCandesartan may increase the nephrotoxic activities of Sodium phosphate.Experimental
Candesartan cilexetilCandesartan cilexetil may increase the nephrotoxic activities of Sodium phosphate.Approved
CandoxatrilCandoxatril may increase the nephrotoxic activities of Sodium phosphate.Experimental
Canrenoic acidCanrenoic acid may increase the nephrotoxic activities of Sodium phosphate.Approved, Withdrawn
CanrenoneCanrenone may increase the nephrotoxic activities of Sodium phosphate.Investigational
CaptoprilCaptopril may increase the nephrotoxic activities of Sodium phosphate.Approved
Carbaspirin calciumSodium phosphate may increase the nephrotoxic activities of Carbaspirin calcium.Experimental, Investigational
CarprofenSodium phosphate may increase the nephrotoxic activities of Carprofen.Approved, Vet Approved, Withdrawn
CaseinCasein can cause a decrease in the absorption of Sodium phosphate resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
CastanospermineSodium phosphate may increase the nephrotoxic activities of Castanospermine.Experimental
CelecoxibSodium phosphate may increase the nephrotoxic activities of Celecoxib.Approved, Investigational
ChloroquineSodium phosphate may increase the nephrotoxic activities of Chloroquine.Approved, Investigational, Vet Approved
ChlorothiazideChlorothiazide may increase the nephrotoxic activities of Sodium phosphate.Approved, Vet Approved
ChlorthalidoneChlorthalidone may increase the nephrotoxic activities of Sodium phosphate.Approved
Choline magnesium trisalicylateSodium phosphate may increase the nephrotoxic activities of Choline magnesium trisalicylate.Approved
CicletanineCicletanine may increase the nephrotoxic activities of Sodium phosphate.Investigational
CilazaprilCilazapril may increase the nephrotoxic activities of Sodium phosphate.Approved
ClofenamideClofenamide may increase the nephrotoxic activities of Sodium phosphate.Experimental
ClomipramineThe risk or severity of adverse effects can be increased when Clomipramine is combined with Sodium phosphate.Approved, Investigational, Vet Approved
ClonixinSodium phosphate may increase the nephrotoxic activities of Clonixin.Approved
ClopamideClopamide may increase the nephrotoxic activities of Sodium phosphate.Experimental
ClorexoloneClorexolone may increase the nephrotoxic activities of Sodium phosphate.Experimental
ConivaptanConivaptan may increase the nephrotoxic activities of Sodium phosphate.Approved, Investigational
CurcuminSodium phosphate may increase the nephrotoxic activities of Curcumin.Approved, Investigational
CyclopenthiazideCyclopenthiazide may increase the nephrotoxic activities of Sodium phosphate.Experimental
CyclothiazideCyclothiazide may increase the nephrotoxic activities of Sodium phosphate.Approved
DelaprilDelapril may increase the nephrotoxic activities of Sodium phosphate.Experimental
DesipramineThe risk or severity of adverse effects can be increased when Desipramine is combined with Sodium phosphate.Approved, Investigational
DibenzepinThe risk or severity of adverse effects can be increased when Dibenzepin is combined with Sodium phosphate.Experimental
DiclofenacSodium phosphate may increase the nephrotoxic activities of Diclofenac.Approved, Vet Approved
DifenpiramideSodium phosphate may increase the nephrotoxic activities of Difenpiramide.Experimental
DiflunisalSodium phosphate may increase the nephrotoxic activities of Diflunisal.Approved, Investigational
DimetacrineThe risk or severity of adverse effects can be increased when Dimetacrine is combined with Sodium phosphate.Approved, Withdrawn
DosulepinThe risk or severity of adverse effects can be increased when Dosulepin is combined with Sodium phosphate.Approved
DoxepinThe risk or severity of adverse effects can be increased when Doxepin is combined with Sodium phosphate.Approved, Investigational
DrospirenoneDrospirenone may increase the nephrotoxic activities of Sodium phosphate.Approved
DroxicamSodium phosphate may increase the nephrotoxic activities of Droxicam.Withdrawn
DuvelisibSodium phosphate may increase the nephrotoxic activities of Duvelisib.Investigational
E-6201Sodium phosphate may increase the nephrotoxic activities of E-6201.Investigational
EfonidipineEfonidipine may increase the nephrotoxic activities of Sodium phosphate.Approved, Investigational
EnalaprilEnalapril may increase the nephrotoxic activities of Sodium phosphate.Approved, Vet Approved
EnalaprilatEnalaprilat may increase the nephrotoxic activities of Sodium phosphate.Approved
EpirizoleSodium phosphate may increase the nephrotoxic activities of Epirizole.Approved
EpitizideEpitizide may increase the nephrotoxic activities of Sodium phosphate.Experimental
EplerenoneEplerenone may increase the nephrotoxic activities of Sodium phosphate.Approved
EprosartanEprosartan may increase the nephrotoxic activities of Sodium phosphate.Approved
Etacrynic acidEtacrynic acid may increase the nephrotoxic activities of Sodium phosphate.Approved, Investigational
EtanerceptSodium phosphate may increase the nephrotoxic activities of Etanercept.Approved, Investigational
EthenzamideSodium phosphate may increase the nephrotoxic activities of Ethenzamide.Experimental
EthoxzolamideEthoxzolamide may increase the nephrotoxic activities of Sodium phosphate.Withdrawn
EtodolacSodium phosphate may increase the nephrotoxic activities of Etodolac.Approved, Investigational, Vet Approved
EtofenamateSodium phosphate may increase the nephrotoxic activities of Etofenamate.Approved, Investigational
EtoricoxibSodium phosphate may increase the nephrotoxic activities of Etoricoxib.Approved, Investigational
Evening primrose oilSodium phosphate may increase the nephrotoxic activities of Evening primrose oil.Investigational, Nutraceutical
ExisulindSodium phosphate may increase the nephrotoxic activities of Exisulind.Investigational
FelbinacSodium phosphate may increase the nephrotoxic activities of Felbinac.Experimental
FenbufenSodium phosphate may increase the nephrotoxic activities of Fenbufen.Approved
FenoprofenSodium phosphate may increase the nephrotoxic activities of Fenoprofen.Approved
FenquizoneFenquizone may increase the nephrotoxic activities of Sodium phosphate.Experimental
FentiazacSodium phosphate may increase the nephrotoxic activities of Fentiazac.Experimental
FeprazoneSodium phosphate may increase the nephrotoxic activities of Feprazone.Experimental
Ferric CarboxymaltoseFerric Carboxymaltose can cause a decrease in the absorption of Sodium phosphate resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Ferric pyrophosphateFerric pyrophosphate can cause a decrease in the absorption of Sodium phosphate resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
Ferulic acidSodium phosphate may increase the nephrotoxic activities of Ferulic acid.Experimental
FimasartanFimasartan may increase the nephrotoxic activities of Sodium phosphate.Approved, Investigational
FloctafenineSodium phosphate may increase the nephrotoxic activities of Floctafenine.Approved, Withdrawn
FlunixinSodium phosphate may increase the nephrotoxic activities of Flunixin.Vet Approved
FlunoxaprofenSodium phosphate may increase the nephrotoxic activities of Flunoxaprofen.Experimental
FlurbiprofenSodium phosphate may increase the nephrotoxic activities of Flurbiprofen.Approved, Investigational
ForasartanForasartan may increase the nephrotoxic activities of Sodium phosphate.Experimental
FosinoprilFosinopril may increase the nephrotoxic activities of Sodium phosphate.Approved
FurosemideFurosemide may increase the nephrotoxic activities of Sodium phosphate.Approved, Vet Approved
GuacetisalSodium phosphate may increase the nephrotoxic activities of Guacetisal.Experimental
HigenamineSodium phosphate may increase the nephrotoxic activities of Higenamine.Investigational
HydrochlorothiazideHydrochlorothiazide may increase the nephrotoxic activities of Sodium phosphate.Approved, Vet Approved
HydroflumethiazideHydroflumethiazide may increase the nephrotoxic activities of Sodium phosphate.Approved, Investigational
HydrotalciteHydrotalcite can cause a decrease in the absorption of Sodium phosphate resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Experimental, Investigational
IbopamineIbopamine may increase the nephrotoxic activities of Sodium phosphate.Experimental
IbuprofenSodium phosphate may increase the nephrotoxic activities of Ibuprofen.Approved
IbuproxamSodium phosphate may increase the nephrotoxic activities of Ibuproxam.Withdrawn
IcatibantSodium phosphate may increase the nephrotoxic activities of Icatibant.Approved, Investigational
ImidaprilImidapril may increase the nephrotoxic activities of Sodium phosphate.Investigational
Imidazole salicylateSodium phosphate may increase the nephrotoxic activities of Imidazole salicylate.Experimental
ImipramineThe risk or severity of adverse effects can be increased when Imipramine is combined with Sodium phosphate.Approved
IndapamideIndapamide may increase the nephrotoxic activities of Sodium phosphate.Approved
IndobufenSodium phosphate may increase the nephrotoxic activities of Indobufen.Investigational
IndomethacinSodium phosphate may increase the nephrotoxic activities of Indomethacin.Approved, Investigational
IndoprofenSodium phosphate may increase the nephrotoxic activities of Indoprofen.Withdrawn
IprindoleThe risk or severity of adverse effects can be increased when Iprindole is combined with Sodium phosphate.Experimental
IrbesartanIrbesartan may increase the nephrotoxic activities of Sodium phosphate.Approved, Investigational
IronIron can cause a decrease in the absorption of Sodium phosphate resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Iron DextranIron Dextran can cause a decrease in the absorption of Sodium phosphate resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Vet Approved
Iron saccharateIron saccharate can cause a decrease in the absorption of Sodium phosphate resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
IsosorbideIsosorbide may increase the nephrotoxic activities of Sodium phosphate.Approved, Investigational
IsoxicamSodium phosphate may increase the nephrotoxic activities of Isoxicam.Withdrawn
KebuzoneSodium phosphate may increase the nephrotoxic activities of Kebuzone.Experimental
KetoprofenSodium phosphate may increase the nephrotoxic activities of Ketoprofen.Approved, Vet Approved
KetorolacSodium phosphate may increase the nephrotoxic activities of Ketorolac.Approved
LeflunomideSodium phosphate may increase the nephrotoxic activities of Leflunomide.Approved, Investigational
LisinoprilLisinopril may increase the nephrotoxic activities of Sodium phosphate.Approved, Investigational
LisofyllineSodium phosphate may increase the nephrotoxic activities of Lisofylline.Investigational
LofepramineThe risk or severity of adverse effects can be increased when Lofepramine is combined with Sodium phosphate.Experimental
LonazolacSodium phosphate may increase the nephrotoxic activities of Lonazolac.Experimental
LornoxicamSodium phosphate may increase the nephrotoxic activities of Lornoxicam.Approved, Investigational
LosartanLosartan may increase the nephrotoxic activities of Sodium phosphate.Approved
LoxoprofenSodium phosphate may increase the nephrotoxic activities of Loxoprofen.Approved, Investigational
LumiracoxibSodium phosphate may increase the nephrotoxic activities of Lumiracoxib.Approved, Investigational
MagaldrateMagaldrate can cause a decrease in the absorption of Sodium phosphate resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Withdrawn
Magnesium carbonateMagnesium carbonate can cause a decrease in the absorption of Sodium phosphate resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
Magnesium hydroxideMagnesium hydroxide can cause a decrease in the absorption of Sodium phosphate resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
Magnesium oxideMagnesium oxide can cause a decrease in the absorption of Sodium phosphate resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Magnesium peroxideMagnesium peroxide can cause a decrease in the absorption of Sodium phosphate resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
Magnesium salicylateSodium phosphate may increase the nephrotoxic activities of Magnesium salicylate.Approved
Magnesium silicateMagnesium silicate can cause a decrease in the absorption of Sodium phosphate resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Magnesium sulfateThe serum concentration of Sodium phosphate can be decreased when it is combined with Magnesium sulfate.Approved, Investigational, Vet Approved
Magnesium TrisilicateMagnesium Trisilicate can cause a decrease in the absorption of Sodium phosphate resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
MannitolMannitol may increase the nephrotoxic activities of Sodium phosphate.Approved, Investigational
MasoprocolSodium phosphate may increase the nephrotoxic activities of Masoprocol.Approved, Investigational
MebutizideMebutizide may increase the nephrotoxic activities of Sodium phosphate.Experimental
Meclofenamic acidSodium phosphate may increase the nephrotoxic activities of Meclofenamic acid.Approved, Vet Approved
Mefenamic acidSodium phosphate may increase the nephrotoxic activities of Mefenamic acid.Approved
MefrusideMefruside may increase the nephrotoxic activities of Sodium phosphate.Experimental
MelitracenThe risk or severity of adverse effects can be increased when Melitracen is combined with Sodium phosphate.Experimental, Investigational
MeloxicamSodium phosphate may increase the nephrotoxic activities of Meloxicam.Approved, Vet Approved
MersalylMersalyl may increase the nephrotoxic activities of Sodium phosphate.Approved
MesalazineSodium phosphate may increase the nephrotoxic activities of Mesalazine.Approved
MetamizoleSodium phosphate may increase the nephrotoxic activities of Metamizole.Approved, Investigational, Withdrawn
MethazolamideMethazolamide may increase the nephrotoxic activities of Sodium phosphate.Approved
MethyclothiazideMethyclothiazide may increase the nephrotoxic activities of Sodium phosphate.Approved
MeticraneMeticrane may increase the nephrotoxic activities of Sodium phosphate.Experimental
MetolazoneMetolazone may increase the nephrotoxic activities of Sodium phosphate.Approved
MizoribineSodium phosphate may increase the nephrotoxic activities of Mizoribine.Investigational
MoexiprilMoexipril may increase the nephrotoxic activities of Sodium phosphate.Approved
MofebutazoneSodium phosphate may increase the nephrotoxic activities of Mofebutazone.Experimental
MuzolimineMuzolimine may increase the nephrotoxic activities of Sodium phosphate.Experimental
Mycophenolate mofetilSodium phosphate may increase the nephrotoxic activities of Mycophenolate mofetil.Approved, Investigational
Mycophenolic acidSodium phosphate may increase the nephrotoxic activities of Mycophenolic acid.Approved
NabumetoneSodium phosphate may increase the nephrotoxic activities of Nabumetone.Approved
NafamostatSodium phosphate may increase the nephrotoxic activities of Nafamostat.Approved, Investigational
NaftifineSodium phosphate may increase the nephrotoxic activities of Naftifine.Approved
NaproxenSodium phosphate may increase the nephrotoxic activities of Naproxen.Approved, Vet Approved
NepafenacSodium phosphate may increase the nephrotoxic activities of Nepafenac.Approved, Investigational
NifenazoneSodium phosphate may increase the nephrotoxic activities of Nifenazone.Experimental
Niflumic AcidSodium phosphate may increase the nephrotoxic activities of Niflumic Acid.Approved
NimesulideSodium phosphate may increase the nephrotoxic activities of Nimesulide.Approved, Investigational, Withdrawn
NitroaspirinSodium phosphate may increase the nephrotoxic activities of Nitroaspirin.Investigational
NortriptylineThe risk or severity of adverse effects can be increased when Nortriptyline is combined with Sodium phosphate.Approved
OlmesartanOlmesartan may increase the nephrotoxic activities of Sodium phosphate.Approved, Investigational
OlopatadineSodium phosphate may increase the nephrotoxic activities of Olopatadine.Approved
OlsalazineSodium phosphate may increase the nephrotoxic activities of Olsalazine.Approved
OmapatrilatOmapatrilat may increase the nephrotoxic activities of Sodium phosphate.Investigational
OpipramolThe risk or severity of adverse effects can be increased when Opipramol is combined with Sodium phosphate.Investigational
OrgoteinSodium phosphate may increase the nephrotoxic activities of Orgotein.Vet Approved
OxaprozinSodium phosphate may increase the nephrotoxic activities of Oxaprozin.Approved
OxyphenbutazoneSodium phosphate may increase the nephrotoxic activities of Oxyphenbutazone.Approved, Withdrawn
PalmidrolSodium phosphate may increase the nephrotoxic activities of Palmidrol.Experimental, Nutraceutical
ParecoxibSodium phosphate may increase the nephrotoxic activities of Parecoxib.Approved
ParthenolideSodium phosphate may increase the nephrotoxic activities of Parthenolide.Approved, Investigational
PerindoprilPerindopril may increase the nephrotoxic activities of Sodium phosphate.Approved
PhenylbutazoneSodium phosphate may increase the nephrotoxic activities of Phenylbutazone.Approved, Vet Approved
PimecrolimusSodium phosphate may increase the nephrotoxic activities of Pimecrolimus.Approved, Investigational
PiretanidePiretanide may increase the nephrotoxic activities of Sodium phosphate.Approved
PirfenidoneSodium phosphate may increase the nephrotoxic activities of Pirfenidone.Approved, Investigational
PiroxicamSodium phosphate may increase the nephrotoxic activities of Piroxicam.Approved, Investigational
PirprofenSodium phosphate may increase the nephrotoxic activities of Pirprofen.Experimental
PolythiazidePolythiazide may increase the nephrotoxic activities of Sodium phosphate.Approved
PotassiumPotassium may increase the nephrotoxic activities of Sodium phosphate.Approved, Investigational
Potassium CitratePotassium Citrate may increase the nephrotoxic activities of Sodium phosphate.Approved, Investigational, Vet Approved
PranoprofenSodium phosphate may increase the nephrotoxic activities of Pranoprofen.Experimental, Investigational
ProglumetacinSodium phosphate may increase the nephrotoxic activities of Proglumetacin.Experimental
PropacetamolSodium phosphate may increase the nephrotoxic activities of Propacetamol.Approved, Investigational
PropyphenazoneSodium phosphate may increase the nephrotoxic activities of Propyphenazone.Experimental
ProquazoneSodium phosphate may increase the nephrotoxic activities of Proquazone.Experimental
ProtriptylineThe risk or severity of adverse effects can be increased when Protriptyline is combined with Sodium phosphate.Approved
PTC299Sodium phosphate may increase the nephrotoxic activities of PTC299.Investigational
QuinaprilQuinapril may increase the nephrotoxic activities of Sodium phosphate.Approved, Investigational
QuinethazoneQuinethazone may increase the nephrotoxic activities of Sodium phosphate.Approved
RamiprilRamipril may increase the nephrotoxic activities of Sodium phosphate.Approved
RescinnamineRescinnamine may increase the nephrotoxic activities of Sodium phosphate.Approved
ResveratrolSodium phosphate may increase the nephrotoxic activities of Resveratrol.Approved, Experimental, Investigational
RofecoxibSodium phosphate may increase the nephrotoxic activities of Rofecoxib.Approved, Investigational, Withdrawn
RolofyllineRolofylline may increase the nephrotoxic activities of Sodium phosphate.Investigational
SacubitrilSacubitril may increase the nephrotoxic activities of Sodium phosphate.Approved
SalicylamideSodium phosphate may increase the nephrotoxic activities of Salicylamide.Approved
Salicylic acidSodium phosphate may increase the nephrotoxic activities of Salicylic acid.Approved, Investigational, Vet Approved
SalsalateSodium phosphate may increase the nephrotoxic activities of Salsalate.Approved
SaprisartanSaprisartan may increase the nephrotoxic activities of Sodium phosphate.Experimental
SaralasinSaralasin may increase the nephrotoxic activities of Sodium phosphate.Investigational
SemapimodSodium phosphate may increase the nephrotoxic activities of Semapimod.Investigational
SeratrodastSodium phosphate may increase the nephrotoxic activities of Seratrodast.Approved
SerrapeptaseSodium phosphate may increase the nephrotoxic activities of Serrapeptase.Investigational
Sodium bicarbonateSodium bicarbonate can cause a decrease in the absorption of Sodium phosphate resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
SpiradolineSpiradoline may increase the nephrotoxic activities of Sodium phosphate.Investigational
SpiraprilSpirapril may increase the nephrotoxic activities of Sodium phosphate.Approved
SpironolactoneSpironolactone may increase the nephrotoxic activities of Sodium phosphate.Approved
SRT501Sodium phosphate may increase the nephrotoxic activities of SRT501.Investigational
SucralfateSucralfate can cause a decrease in the absorption of Sodium phosphate resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
SulfasalazineSodium phosphate may increase the nephrotoxic activities of Sulfasalazine.Approved
SulindacSodium phosphate may increase the nephrotoxic activities of Sulindac.Approved, Investigational
SuprofenSodium phosphate may increase the nephrotoxic activities of Suprofen.Approved, Withdrawn
SuxibuzoneSodium phosphate may increase the nephrotoxic activities of Suxibuzone.Experimental
TarenflurbilSodium phosphate may increase the nephrotoxic activities of Tarenflurbil.Investigational
TasosartanTasosartan may increase the nephrotoxic activities of Sodium phosphate.Approved
TelmisartanTelmisartan may increase the nephrotoxic activities of Sodium phosphate.Approved, Investigational
TemocaprilTemocapril may increase the nephrotoxic activities of Sodium phosphate.Experimental, Investigational
TenidapSodium phosphate may increase the nephrotoxic activities of Tenidap.Experimental
TenoxicamSodium phosphate may increase the nephrotoxic activities of Tenoxicam.Approved
TepoxalinSodium phosphate may increase the nephrotoxic activities of Tepoxalin.Vet Approved
TeriflunomideSodium phosphate may increase the nephrotoxic activities of Teriflunomide.Approved
TheobromineTheobromine may increase the nephrotoxic activities of Sodium phosphate.Approved, Investigational
TianeptineThe risk or severity of adverse effects can be increased when Tianeptine is combined with Sodium phosphate.Approved, Investigational
Tiaprofenic acidSodium phosphate may increase the nephrotoxic activities of Tiaprofenic acid.Approved
TicrynafenTicrynafen may increase the nephrotoxic activities of Sodium phosphate.Withdrawn
TinoridineSodium phosphate may increase the nephrotoxic activities of Tinoridine.Investigational
Tolfenamic AcidSodium phosphate may increase the nephrotoxic activities of Tolfenamic Acid.Approved, Investigational
TolmetinSodium phosphate may increase the nephrotoxic activities of Tolmetin.Approved
TolvaptanTolvaptan may increase the nephrotoxic activities of Sodium phosphate.Approved
TorasemideTorasemide may increase the nephrotoxic activities of Sodium phosphate.Approved
TrandolaprilTrandolapril may increase the nephrotoxic activities of Sodium phosphate.Approved
TranilastSodium phosphate may increase the nephrotoxic activities of Tranilast.Approved, Investigational
TriamtereneTriamterene may increase the nephrotoxic activities of Sodium phosphate.Approved
TribenosideSodium phosphate may increase the nephrotoxic activities of Tribenoside.Experimental
TrichlormethiazideTrichlormethiazide may increase the nephrotoxic activities of Sodium phosphate.Approved, Vet Approved
TrimipramineThe risk or severity of adverse effects can be increased when Trimipramine is combined with Sodium phosphate.Approved
TriptolideSodium phosphate may increase the nephrotoxic activities of Triptolide.Investigational
TromethamineTromethamine can cause a decrease in the absorption of Sodium phosphate resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
UlaritideUlaritide may increase the nephrotoxic activities of Sodium phosphate.Investigational
ValdecoxibSodium phosphate may increase the nephrotoxic activities of Valdecoxib.Approved, Investigational, Withdrawn
ValsartanValsartan may increase the nephrotoxic activities of Sodium phosphate.Approved, Investigational
XipamideXipamide may increase the nephrotoxic activities of Sodium phosphate.Experimental
ZaltoprofenSodium phosphate may increase the nephrotoxic activities of Zaltoprofen.Approved, Investigational
ZileutonSodium phosphate may increase the nephrotoxic activities of Zileuton.Approved, Investigational, Withdrawn
ZofenoprilZofenopril may increase the nephrotoxic activities of Sodium phosphate.Experimental
ZomepiracSodium phosphate may increase the nephrotoxic activities of Zomepirac.Withdrawn
Food Interactions
Not Available

References

General References
  1. Rex DK: Dosing considerations in the use of sodium phosphate bowel preparations for colonoscopy. Ann Pharmacother. 2007 Sep;41(9):1466-75. Epub 2007 Jul 24. [PubMed:17652123]
  2. Schanz S, Kruis W, Mickisch O, Kuppers B, Berg P, Frick B, Heiland G, Huppe D, Schenck B, Horstkotte H, Winkler A: Bowel Preparation for Colonoscopy with Sodium Phosphate Solution versus Polyethylene Glycol-Based Lavage: A Multicenter Trial. Diagn Ther Endosc. 2008;2008:713521. doi: 10.1155/2008/713521. [PubMed:18645612]
  3. Ehrenpreis ED: Increased serum phosphate levels and calcium fluxes are seen in smaller individuals after a single dose of sodium phosphate colon cleansing solution: a pharmacokinetic analysis. Aliment Pharmacol Ther. 2009 Jun 1;29(11):1202-11. doi: 10.1111/j.1365-2036.2009.03987.x. Epub 2009 Feb 27. [PubMed:19298584]
  4. Razzaque MS: Phosphate toxicity: new insights into an old problem. Clin Sci (Lond). 2011 Feb;120(3):91-7. doi: 10.1042/CS20100377. [PubMed:20958267]
  5. Biber J, Hernando N, Forster I: Phosphate transporters and their function. Annu Rev Physiol. 2013;75:535-50. doi: 10.1146/annurev-physiol-030212-183748. [PubMed:23398154]
  6. FDA Guide: Sodium Phosphate Tablet [Link]
  7. ChemIDPlus: Sodium Phosphate [Link]
External Links
PubChem Compound
23672064
PubChem Substance
347827853
ChemSpider
22626
ChEBI
37585
ChEMBL
CHEMBL1368
Wikipedia
Sodium_phosphates
ATC Codes
A06AD17 — Sodium phosphateB05XA09 — Sodium phosphateA06AG01 — Sodium phosphate
FDA label
Download (359 KB)
MSDS
Download (84.7 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1CompletedPreventionPlasmodium Infections1
2CompletedBasic ScienceColonoscopy1
2CompletedScreeningHealthy Volunteers1
3Active Not RecruitingTreatmentX-Linked Hypophosphatemia1
3CompletedNot AvailableColonoscopy1
3CompletedDiagnosticBowel Preparation, Efficacy, Tolerability, Safety1
3CompletedTreatmentCataracts2
3CompletedTreatmentColon Cleansing1
3CompletedTreatmentColonoscopy2
4CompletedNot AvailableEye Dryness1
4CompletedDiagnosticColonoscopy1
4CompletedOtherSickle Cell Disorders1
4CompletedTreatmentColon Cleansing1
4CompletedTreatmentColonoscopy2
4CompletedTreatmentColorectal Cleansing Prior Operation1
4CompletedTreatmentPsoriasis / Sleep Apnea, Obstructive1
4Not Yet RecruitingBasic ScienceHeart Defects,Congenital1
4RecruitingTreatmentTransient Hypoparathyroidism1
Not AvailableCompletedOtherLaparoscopic Hysterectomy and/or Laparoscopic Sacrocolpopexy1
Not AvailableCompletedScreeningColorectal Cancers1
Not AvailableRecruitingNot AvailableHealthy Adults1
Not AvailableRecruitingOtherChronic Kidney Disease (CKD)1
Not AvailableTerminatedTreatmentColonoscopy1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
FormRouteStrength
SolutionUnknown
TabletOral
Powder, for solutionIntraocular
Injection, solutionIntravenous
Kit
Kit; solutionIntraocular
LiquidIntravenous
SolutionIntravenous
PasteDental
InjectionIntrathecal
KitIntravenous
LiquidRectal
SolutionExtracorporeal
LiquidIntravesical
Kit
LiquidBuccal
SprayBuccal
KitIntravenous
Kit; solutionIntraocular; Irrigation
LiquidTopical
Tablet, effervescentOral
RinseDental
SolutionOral
EnemaRectal
LiquidOral
SolutionRespiratory (inhalation)
PowderOral
IrrigantIrrigation
LiquidIrrigation
CapsuleOral
Tablet, coatedOral
Prices
Not Available
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US7687075No2008-06-222028-06-22Us
US7084130No2001-11-292021-11-29Us

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)Decomposes at 75MSDS
water solubility121 g/LMSDS
Predicted Properties
PropertyValueSource
logP-1ChemAxon
pKa (Strongest Acidic)1.8ChemAxon
Physiological Charge-2ChemAxon
Hydrogen Acceptor Count4ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area80.59 Å2ChemAxon
Rotatable Bond Count0ChemAxon
Refractivity13.53 m3·mol-1ChemAxon
Polarizability5.53 Å3ChemAxon
Number of Rings0ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available

Taxonomy

Description
This compound belongs to the class of inorganic compounds known as alkali metal phosphates. These are inorganic compounds in which the largest oxoanion is phosphate, and in which the heaviest atom not in an oxoanion is an alkali metal.
Kingdom
Inorganic compounds
Super Class
Mixed metal/non-metal compounds
Class
Alkali metal oxoanionic compounds
Sub Class
Alkali metal phosphates
Direct Parent
Alkali metal phosphates
Alternative Parents
Inorganic sodium salts / Inorganic oxides
Substituents
Alkali metal phosphate / Inorganic sodium salt / Inorganic oxide / Inorganic salt
Molecular Framework
Not Available
External Descriptors
sodium phosphate (CHEBI:37585)

Transporters

Kind
Protein
Organism
Human
Pharmacological action
No
Actions
Substrate
General Function
Not Available
Specific Function
Not Available
Gene Name
SLC20A1
Uniprot ID
Q8WUM9
Uniprot Name
Sodium-dependent phosphate transporter 1
Molecular Weight
73699.01 Da
References
  1. Biber J, Hernando N, Forster I: Phosphate transporters and their function. Annu Rev Physiol. 2013;75:535-50. doi: 10.1146/annurev-physiol-030212-183748. [PubMed:23398154]
Kind
Protein
Organism
Homo sapiens
Pharmacological action
No
Actions
Substrate
General Function
Virus receptor activity
Specific Function
Sodium-phosphate symporter which seems to play a fundamental housekeeping role in phosphate transport by absorbing phosphate from interstitial fluid for normal cellular functions such as cellular m...
Gene Name
SLC20A2
Uniprot ID
Q08357
Uniprot Name
Sodium-dependent phosphate transporter 2
Molecular Weight
70391.755 Da
References
  1. Biber J, Hernando N, Forster I: Phosphate transporters and their function. Annu Rev Physiol. 2013;75:535-50. doi: 10.1146/annurev-physiol-030212-183748. [PubMed:23398154]
Kind
Protein
Organism
Homo sapiens
Pharmacological action
No
Actions
Substrate
General Function
Sodium:phosphate symporter activity
Specific Function
Involved in actively transporting phosphate into cells via Na(+) cotransport in the renal brush border membrane. Probably mediates 70-80% of the apical influx.
Gene Name
SLC34A1
Uniprot ID
Q06495
Uniprot Name
Sodium-dependent phosphate transport protein 2A
Molecular Weight
68936.53 Da
References
  1. Biber J, Hernando N, Forster I: Phosphate transporters and their function. Annu Rev Physiol. 2013;75:535-50. doi: 10.1146/annurev-physiol-030212-183748. [PubMed:23398154]
Kind
Protein
Organism
Homo sapiens
Pharmacological action
No
Actions
Substrate
General Function
Sodium:phosphate symporter activity
Specific Function
May be involved in actively transporting phosphate into cells via Na(+) cotransport. It may be the main phosphate transport protein in the intestinal brush border membrane. May have a role in the s...
Gene Name
SLC34A2
Uniprot ID
O95436
Uniprot Name
Sodium-dependent phosphate transport protein 2B
Molecular Weight
75758.535 Da
References
  1. Biber J, Hernando N, Forster I: Phosphate transporters and their function. Annu Rev Physiol. 2013;75:535-50. doi: 10.1146/annurev-physiol-030212-183748. [PubMed:23398154]
Kind
Protein
Organism
Homo sapiens
Pharmacological action
No
Actions
Substrate
General Function
Sodium:phosphate symporter activity
Specific Function
May be involved in actively transporting phosphate into cells via Na(+) cotransport in the renal brush border membrane. Probably mediates 20-30% of the apical influx.
Gene Name
SLC34A3
Uniprot ID
Q8N130
Uniprot Name
Sodium-dependent phosphate transport protein 2C
Molecular Weight
63548.94 Da
References
  1. Kirchheiner J, Meineke I, Muller G, Roots I, Brockmoller J: Contributions of CYP2D6, CYP2C9 and CYP2C19 to the biotransformation of E- and Z-doxepin in healthy volunteers. Pharmacogenetics. 2002 Oct;12(7):571-80. [PubMed:12360109]

Drug created on November 30, 2015 12:10 / Updated on June 19, 2018 06:44